Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEMETREXED DITROMETHAMINE vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent purine and pyrimidine synthesis, leading to disruption of DNA synthesis and cell death.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
FDA-approved: In combination with cisplatin for initial treatment of patients with malignant pleural mesothelioma who are unresectable or not surgical candidates.,FDA-approved: As a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior platinum-based chemotherapy.,FDA-approved: In combination with pembrolizumab and platinum chemotherapy for first-line treatment of metastatic non-squamous NSCLC.,Off-label: Treatment of recurrent or metastatic cervical cancer, breast cancer, bladder cancer, colorectal cancer, and others.
Management of mild to moderate pain,Reduction of fever
500 mg/m2 intravenously over 10 minutes every 21 days.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal half-life 3.5 hours (range 2.5-5.0 hours) in patients with normal renal function; prolonged to 5-10 hours in moderate renal impairment. Clinical context: Half-life is dose-independent; clearance correlates with creatinine clearance.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Pemetrexed is primarily excreted unchanged in the urine. It undergoes minimal hepatic metabolism; less than 5% is metabolized by the liver.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily renal excretion: 70-90% of the dose is eliminated unchanged in urine within 24 hours. Fecal excretion accounts for <5%.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
81% bound primarily to albumin; minimal binding to alpha-1-acid glycoprotein.
10-25% bound to albumin at therapeutic concentrations.
Vd at steady state = 16.1 L/m² (approximately 0.4 L/kg in adults). Clinical meaning: Indicates distribution into total body water with limited tissue binding; low Vd suggests minimal extravascular distribution.
0.8-1.0 L/kg; suggests distribution into total body water.
Intravenous only; bioavailability is 100% by IV route. Not orally available due to poor absorption and extensive first-pass metabolism.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
Cr Cl ≥45 m L/min: 500 mg/m2; Cr Cl 30-44 m L/min: 375 mg/m2; Cr Cl <30 m L/min: not recommended.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
No dose adjustment recommended for Child-Pugh A or B. Child-Pugh C: no data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Not established; safety and efficacy not determined in pediatric patients.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
No specific dose adjustment; monitor renal function closely due to age-related decline in Cr Cl.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Pemetrexed can cause severe or fatal hypersensitivity reactions, including anaphylaxis. It also causes severe myelosuppression, which may require dose modification or discontinuation. Patients must be pretreated with corticosteroids and vitamin supplementation to reduce toxicity.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Myelosuppression: Dose-dependent, monitor blood counts regularly.,Renal toxicity: Excreted renally; adjust dose in renal impairment (Cr Cl <45 m L/min).,Gastrointestinal toxicity: Nausea, vomiting, diarrhea; may require antiemetics.,Hypersensitivity reactions: Premedicate with corticosteroids.,Folic acid and vitamin B12 deficiency: Supplement to reduce hematologic toxicity.,Third-space fluid accumulation: Consider drainage before treatment.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
History of severe hypersensitivity reaction to pemetrexed or any excipients.,Concurrent yellow fever vaccine (risk of systemic fatal disease).,Severe renal impairment (Cr Cl <45 m L/min) not meeting criteria for dose adjustment.
Hypersensitivity to acetaminophen or any component of the formulation
No specific dietary restrictions. However, folic acid supplements and vitamin B12 are required. Avoid folic acid antagonists like methotrexate.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Pemetrexed is a folate analog metabolic inhibitor that is teratogenic in animals. In humans, it is contraindicated in pregnancy due to its mechanism of action interfering with DNA synthesis and cell division. First trimester exposure carries the highest risk of major congenital malformations (e.g., neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and potential fetal demise. Use in pregnant women is not recommended unless no safer alternative exists.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
There are no data on the presence of pemetrexed in human milk, its effects on the breastfed infant, or milk production. Due to the potential for serious adverse reactions in nursing infants (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is not recommended during pemetrexed therapy and for at least one week after the last dose. The M/P ratio is unknown.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No specific dosing adjustments for pregnancy are established due to lack of data. Physiologic changes in pregnancy (increased renal clearance, expanded plasma volume) may reduce drug exposure, but dose increases are not recommended due to potential fetal toxicity. In animal studies, lower doses produced embryotoxicity. Therefore, dose adjustments should not be made; the drug should be avoided in pregnancy.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Administer folic acid and vitamin B12 supplementation to reduce toxicity. Premedicate with corticosteroids to prevent rash. Monitor renal function; dose adjust for Cr Cl <45 m L/min. Avoid NSAIDs for 2 days before and after dose. Ensure adequate hydration. Do not mix with calcium-containing solutions.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take folic acid daily and vitamin B12 injections every 9 weeks as prescribed.,Inform all healthcare providers about your treatment; avoid NSAIDs like ibuprofen or naproxen.,Report new or worsening rash, diarrhea, or mouth sores immediately.,Drink plenty of fluids to stay hydrated.,Avoid receiving live vaccines during treatment.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
"Methotrimeprazine may reduce the gastrointestinal absorption of tromethamine, an alkalinizing agent, leading to decreased systemic exposure and potentially diminished therapeutic efficacy. This interaction is hypothesized to occur via altered gastric pH or motility, though direct evidence is limited. Patients may experience reduced effectiveness of tromethamine in managing acid-base disorders."
"Tromethamine, an alkalinizing agent used to correct metabolic acidosis, can increase gastric pH, which may reduce the absorption of weakly acidic drugs like estrone sulfate. This altered gastrointestinal environment can decrease estrone sulfate bioavailability, potentially compromising its systemic effects for hormone replacement therapy. Clinically, this may lead to reduced efficacy of estrone sulfate, requiring dose adjustments or alternative administration routes."
"Tromethamine, an alkalinizing agent, can increase urinary pH, which enhances the renal excretion of sotalol, a class III antiarrhythmic that is primarily eliminated unchanged by the kidneys. This interaction may lead to reduced serum sotalol concentrations, potentially decreasing its therapeutic efficacy and increasing the risk of arrhythmia recurrence, particularly in patients with renal impairment or those requiring precise antiarrhythmic control."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEMETREXED DITROMETHAMINE vs INJECTAPAP, answered by our medical review team.
PEMETREXED DITROMETHAMINE is a Antineoplastic Antifolate that works by Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent purine and pyrimidine synthesis, leading to disruption of DNA synthesis and cell death.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEMETREXED DITROMETHAMINE and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEMETREXED DITROMETHAMINE is: 500 mg/m2 intravenously over 10 minutes every 21 days.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEMETREXED DITROMETHAMINE and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEMETREXED DITROMETHAMINE is classified as Category C. Pemetrexed is a folate analog metabolic inhibitor that is teratogenic in animals. In humans, it is contraindicated in pregnancy due to its mechanism of action interfering with DNA . INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.